The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Https://neurosciencenews.com/uk-alzheimers-blood-test-25867/
The new Tau test is from Alzpath (https://alzpath.bio/about/)
Shows university of Gothenburg is a partner in the evaluation.
Is the new p-tau217 test using Bioventix antibodies. Even if not, it is good news for Bioventix p-tau217 new assay for Alzheimer's.
https://www.bbc.co.uk/news/health-68726703
Maxcyte is like Abzena. I remember Abzena also had a high cash burn rate, was loss making and had lots of licences for royalties on the drugs that got to market by their customers. The market cap was continously eaten away untill it was bought out for a fraction of its value.
I think this could happen here.
x25 earnings is a little high if the growth has stalled (NT-proBNP: £1.28 million has now permanently gone from the revenue stream).
Hopefully, they can get some extra revenue from other sources than just the troponin antibody to make up for the shortfall.
Hi Rooky,
With the new results the P/E goes down to 27. Very reasonable considering it has strong growth and it is not affected by the slow down to much. Not to mention the special dividend and dividend. I make that 141p for the year and a 3.3% div yield.
This is the sort of share to buy and hold. Also the total issued shares has not changed by much for the last 5 years. So you are not getting diluted for this growth.
Wonderfull results I have bought back in. The growth has been from the T3 and anti- drug testing antibody in the UK and rest of the world/china. From R&D projects and product revenue. It seems whenever they can see a revenue drop (e.g. testosterone/estradiol/NT-proBNP) testing they seem to be able to go out and get new R&D projects from their partners to fill the revenue gap. Anti-Troponin antibody role out is very slow but it is building.
Looking through the companies last presentation they warn that COVID may affect the use of core antibodies in the lab.
The Vit D antibody is 52% of revenue for example. The others are related to non-emergency thryoxine testing and fertily testing mainly. The hospitals and doctors have had non-critical use significantly reduced during the COVID crisis. I think the next set of results will show a big down turn in revenue.
I am starting to think that the demand for testing people in quarantine for Vit D levels will be greatly reduced! The virus outbreak could also affect testing of people for reproductive hormones. As fertility testing is put on hold and COVID patients are prioritised.
https://beta.companieshouse.gov.uk/company/11321836/filing-history
Did any one catch the podcast. Is there any further info available. https://www.*************.com/views/31792/tom-winnifrith-bearcast-adam-reynolds-new-departure-loopup-stinks-praise-for-the-sfo-fcr
Here is a explanation of the distributable reserves in the annual report. http://www.stockopedia.com/content/small-cap-value-report-6-jan-2017-craw-zyt-g4m-165336/
"Special business resolution number five proposes that the Company undertakes a court approved capital reduction process designed to convert £8.9m of non-distributable reserves into distributable reserves." Looks like a good use of spare cash for the benefit of shareholders.